SCHEMBL702375

SCHEMBL702375

NCc1n[nH]c2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 6/20 0.61
KDM4E B2RXH2 4/20 0.57
GAA P10253 2/20 0.57
PDPK1 O15530 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP1A2 P05177 2/20 0.49
CYP2D6 P10635 1/20 0.49
ALDH1A1 P00352 2/20 0.48
IDO1 P14902 2/20 0.48
ALPL P05186 1/20 0.48
HPGD P15428 1/20 0.48
TTK P33981 1/20 0.48
MAPK10 P53779 1/20 0.48
AURKA O14965 1/20 0.43
LRRK2 Q5S007 2/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
RAB9A P51151 1/20 0.42
ITK Q08881 1/20 0.41
WDR77 Q9BQA1 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4552790 0.85 PRMT5 (0.47) PRMT5KDM4EGAAPDPK1CYP3A4
SCHEMBL700944 0.84 KDM4E (0.53) PRMT5KDM4EGAAPDPK1CYP3A4
Hydrochloric Acid SCHEMBL892688 0.82 KDM4E (0.52) PRMT5KDM4EGAAPDPK1CYP3A4
Hydrochloric Acid SCHEMBL31547777 0.82 KDM4E (0.52) PRMT5KDM4EGAAPDPK1CYP3A4
SCHEMBL2071550 0.81 KDM4E (0.50) PRMT5KDM4EGAAPDPK1CYP3A4
SCHEMBL2227955 0.79 KDM4E (0.52) PRMT5KDM4EGAAPDPK1CYP3A4
SCHEMBL960630 0.79 KDM4E (0.52) KDM4EGAAPDPK1CYP3A4CYP1A2
SCHEMBL730574 0.79 KDM4E (0.52) PRMT5KDM4EGAAPDPK1CYP3A4
SCHEMBL16182225 0.79 KDM4E (0.52) PRMT5KDM4EGAAPDPK1CYP3A4
SCHEMBL3061437 0.79 KDM4E (0.52) PRMT5KDM4EGAAPDPK1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3510404-A1 CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF Pharmakea, Inc. (US) 2019-07-17 EP claimed
US-20190192697-A1 CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF PHARMAKEA, INC. 2019-06-27 US claimed
WO-2018048928-A1 CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF PHARMAKEA, INC. (US) 2018-03-15 WO claimed
WO-2026101698-A1 HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF PROTAGONIST THERAPEUTICS, INC. (US) 2026-05-15 WO disclosed
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
EP-4452936-A2 INDOLES, INDAZOLES, AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD The Katholieke Universiteit Leuven (BE) 2024-10-30 EP disclosed
CN-115052860-B Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2024-06-21 CN disclosed
US-20240067631-A1 PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS CYTOKINETICS, INC. 2024-02-29 US disclosed
EP-4240736-A1 PPAR GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2023-09-13 EP disclosed
US-20230202985-A1 Indoles, Indazoles, and Related Analogs for Inhibiting YAP/TAZ-TEAD CISTIM LEUVEN VZW (BE) 2023-06-29 US disclosed
WO-2023122782-A2 INDOLES, INDAZOLES, AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-06-29 WO disclosed
US-7094909-B2 Reacting an amide compound containing hydroxy and a carboxyl group and having benzene ring, with a halogenated alkyl aminocarbonyl-pyrrolidine with 2-fluoro groups substituted at the ring carbon, by amindation of amine and carboxyl group AGOURON PHARMACEUTICALS, INC. (US) 2006-08-22 US disclosed
WO-2004065305-A1 NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON MANGANESE UNIVERSITY OF DAYTON (US) 2004-08-05 WO disclosed
EP-1409466-A2 HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS AGOURON PHARMACEUTICALS, INC. (US) 2004-04-21 EP disclosed
US-20030225071-A1 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis PFIZER INC. 2003-12-04 US disclosed
WO-2003060192-A1 NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT UNIVERSITY OF DAYTON (US) 2003-07-24 WO disclosed
WO-2002100844-A2 HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS AGOURON PHARMACEUTICALS, INC. (US) 2002-12-19 WO disclosed
US-4006239-A Benzoic acid amides for mycobacterium infections BAYER AKTIENGESELLSCHAFT (DT) 1977-02-01 US disclosed
US-3995044-A Pyridine carboxylic acid amides for mycobacterium infections BAYER AKTIENGESELLSCHAFT (DT) 1976-11-30 US disclosed
US-3956312-A ANTISECRETORY AGENT EGYT GYOGYSZERVEGYESZETI GYAR (HU) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202985-A1 Indoles, Indazoles, and Related Analogs for Inhibiting YAP/TAZ-TEAD YAP1, TEAD2, TEAD3 PRMT5 190/4885KDM4E 961/4885GAA 3965/4885
US-20030225071-A1 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis SERPINB1, FURIN, PEPD PRMT5 1222/4885KDM4E 2248/4885GAA 53/4885
US-20240067631-A1 PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS NAMPT, NNT, NAPRT PRMT5 336/4885KDM4E 3301/4885GAA 2079/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD PRMT5 2157/4885KDM4E 2304/4885GAA 3930/4885
US-20190192697-A1 CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF LOXL2, LOXL1, LOXL3 PRMT5 4028/4885KDM4E 3469/4885GAA 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.